
|Articles|November 7, 2012
Device delivers glaucoma medication
In a pilot phase II study, an intracanalicular plug (OTX-TP2, Ocular Therapeutics) shows promise for lowering IOP and increasing compliance with the treatment regimen.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025: Advancements in laser refractive surgery
2
From then to next: Five decades of transformation in ophthalmology
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
5


















































.png)


